Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Single, dual and pan-Peroxisome proliferator-activated receptor (PPAR) agonists are under development for the pharmacological treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD) / NASH
Owing to their key role in the transcriptional regulation of glucose and lipid metabolism, PPAR ligands hold promise as therapeutic agents for NAFLD
Liss & Finck …